AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart ...
Research Triangle Park, North Carolina Saturday, February 15, 2025, 17:00 Hrs [IST] ...
HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...
Clinical Trial Application for global Phase 3 trials with nizubaglustat in GM1/GM2 gangliosidoses and Niemann-Pick Disease Type C approved in multiple European countries, anticipated to begin in ...
Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...
Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...
Nemluviois the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 ...
Detailed price information for Thiogenesis Therapeutics Corp (TTI-X) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback